HSP90AA1 and gastric cancer: Additionally, we integrated four independent prognostic factors—HSP90, NLR, treatment lines, and metastatic sites—to construct a novel and convenient nomogram model for assessing the prognosis of gastric cancer patients receiving PD-1 inhibitor therapy, which aids in identifying potential beneficiaries of immunotherapy.